Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., May 28 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 31 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 151,800 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other clinical and preclinical drug development candidates and programs that have not been determined to be safe or effective in humans for any uses.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
(Date:10/12/2015)... Oct. 12, 2015 VolitionRx Limited (NYSE ... clinical study of its NuQ ® blood-based test for ... issue of Clinical Epigenetics , the official journal of ... collaboration with Lund University, ... MD, PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. ...
(Date:10/12/2015)... , ... October 12, 2015 , ... LifeTrak , ... launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to meet ... flexwear technology and accurate heart rate monitoring both in water and on ...
(Date:10/10/2015)... 2015 Am 8. Oktober hat die ... für Kalifornien) ihre Würdigung der International Plasma Awareness ... Aufzeichnungen des Kongresses eintragen lassen. Die IPAW wird ... (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre Ziele bestehen ... über Plasmaspenden weltweit , Würdigung des Beitrages ...
Breaking Biology Technology:
(Date:10/8/2015)... , 8. Oktober 2015 ... global tätiges Unternehmen des Bereiches Tracking, hat ... mit der Gefängnisbehörde Virginias (Department of Corrections ... elektronische Überwachungsdienste für alle Strafen geliefert werden, ... Cassell , Präsident für den Amerikanischen Kontinent ...
(Date:10/6/2015)... SAN MATEO, Calif. , Oct. 6, 2015 ... software company, today announced enhancements to its software ... gene expression analysis kit for differential expression in ... Analytic Platform, which is a cloud-based genomic analysis ... to advance scientific discovery from next-generation sequencing efforts. ...
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
Breaking Biology News(10 mins):